Corpus overview


Overview

MeSH Disease

Human Phenotype

Rhinitis (6)

Cough (3)

Fever (3)

Asthma (2)

Hypertension (1)


Transmission

Seroprevalence
    displaying 1 - 6 records in total 6
    records per page




    Socio-demographic, clinical, hospital admission and oxygen requirement characteristics of COVID-19 patients of Bangladesh

    Authors: Ratindra Nath Mondal; Md. Abdur Razzak Sarker; Anupom Das; M. Ahsanul Kabir Ahsan; Shah Md Sarwer Jahan; Aklima Sultana; Jafrin Sultana; Moni Rani

    doi:10.1101/2020.08.14.20175018 Date: 2020-08-16 Source: medRxiv

    Abstract Background: Clinical presentation hospital admission and outcome of COVID-19 pandemic are different from one country to another. So every country should have their own data regarding COVID-19. Subjects and Methods: This was an online cross-sectional survey carried out in RT-PCR positive COVID-19 adult TRANS patient. A preformed questionnaire adapted in Google form and circulated through online to collect data. Informed consent was ensured before participation in this study. Results: We have studied of 305 RT-PCR positive COVID-19 patients mean age TRANS was 36.32(+/-12.369) years with male TRANS predominance and majority were doctor 46.9%. 48.8% of the patients family members TRANS affected along with them. After COVID-19 pandemic 31.7% did not go out of their house. For prevention (72.4%)of the patients used mask and 38.8% used hand gloves during outing. 28.7% reported to be affected while working in hospital 21.8%were affected in their office. Fever HP Fever MESHD (80.1%) cough HP (57.7%) pain HP pain MESHD in throat (50.8%) rhinitis HP rhinitis MESHD (45.9%) and loss of smell (45%) and taste sensation (45.6%) were the most common symptoms. Sample was given average 3 (+/- 3.384) days after onset of the symptoms TRANS and report was delivered average 4.57 days after giving sample. After getting result 32.1% of the patients seek treatment in telemedicine and 23% directly consulted in Government hospital only 2% reported to be treated by the Government designated telephone number. 73.1% of the patient took both steam inhalation and warm water gargling. Paracetamol and antihistamine was the most commonly use drugs 69.8% and 71.5% respectively besides 47.5% took ivermectin 41.6% took azithromycin 35.1% steroid 34.8% took doxycyclin and 21.6% hydroxychloroquine. Among the patients only 20.3% needed hospital admission. The patients admitted in hospital average 5 (+/-3.922) days after onset of symptoms TRANS and hospital staying was 9.2 days (average). Breathless (54.83%) was the major cause of hospital admission and 19.35% patients admitted due to fear. 14% patients needed oxygen and average duration of oxygen was 4.84 days. 81.3% patients has taken oxygen in hospital and 18.8% at their home. Among the patient 2.2% needed ICU and artificial ventilation needed for 1.1% patients. The patients recovered after 17.74 days (average) from the onset of symptom TRANS. COVID-19 became negative (RT-PCR) at15th day from onset of symptom TRANS. 91.8%) were in mental stress to become the cause of infection MESHD spread to other family members TRANS 20.7%) reported that they were anxious that they would not get oxygen or ICU if required and 27.9% were suffering from fear of death MESHD. Weakness was the most common post disease symptom in 57.4% cases. Average time required for coming back to normal life was 21.59 days (+/-7.901) ranging a wide range from 5 to 60 days. Conclusion: COVID-19 patients were mostly male TRANS health worker. Fever HP Fever MESHD cough HP pain HP in throat were most common symptoms. Hospital admission required in only one-fifth cases and ICU required for only 2% patients. Weakness was the most common post disease symptom. Keywords: COVID Bangladesh oxygen ivermectin Correspondence Dr. Ratindra Nath Mondal President Society of General Physician Founder-Daktarkhana (GP center) Rangpur Bangladesh Email dr.ratinmondal@gmail.com.

    The impact of COVID-19 on patients with asthma HP asthma MESHD: A Big Data analysis

    Authors: Jose Luis Izquierdo; Carlos Almonacid; Yolanda Gonzalez; Carlos Del Rio-Bermudez; Julio Ancochea; Remedios Cardenas; Joan B Soriano

    doi:10.1101/2020.07.24.20161596 Date: 2020-07-24 Source: medRxiv

    Background: From the onset of the COVID-19 pandemic, an association between the severity of COVID-19 and the presence of certain medical chronic conditions has been suggested. However, unlike influenza and other viruses, the burden of the disease in patients with asthma HP asthma MESHD has been less evident. Objective: This study aims at a better understanding of the burden of COVID-19 in patients with asthma HP asthma MESHD and the impact of asthma HP, its related comorbidities, and treatment on the prognosis of COVID-19. Methods: We analyzed clinical data from patients with asthma HP asthma MESHD from January 1st to May 10th, 2020 using big data analytics and artificial intelligence through the SAVANA Manager clinical platform. Results: Out of 71,192 patients with asthma HP asthma MESHD, 1,006 (1.41%) suffered from COVID-19. Compared to asthmatic individuals without COVID-19, patients with asthma HP asthma MESHD and COVID-19 were significantly older (55 vs. 42 years), predominantly female TRANS (66% vs. 59%), had higher prevalence SERO of hypertension HP hypertension MESHD, dyslipidemias MESHD, diabetes MESHD, and obesity HP obesity MESHD, and smoked more frequently. Contrarily, allergy HP allergy MESHD-related factors such as rhinitis HP rhinitis MESHD and eczema HP eczema MESHD were less frequent in asthmatic patients with COVID-19 (P < .001). Higher prevalence SERO of hypertension HP hypertension MESHD, dyslipidemia MESHD, diabetes MESHD, and obesity HP obesity MESHD was also confirmed in those patients with asthma HP asthma MESHD and COVID-19 who required hospital admission. The percentage of individuals using inhaled corticosteroids ( ICS MESHD) was lower in patients who required hospitalization due to COVID-19, as compared to non-hospitalized patients (48.3% vs. 61.5%; OR: 0.58: 95% CI 0.44-0.77). During the study period, 865 (1.21%) patients with asthma HP asthma MESHD were being treated with biologics. Although these patients showed increased severity and more comorbidities at the ear, nose, and throat (ENT) level, their hospital admission rates due to COVID-19 were relatively low (0.23%). COVID-19 increased inpatient mortality in asthmatic patients (2.29% vs 0.54%; OR 2.29: 95% CI 4.35-6.66). Conclusion: Our results indicate that the number of COVID-19 cases in patients with asthma HP has been low, although higher than the observed in the general population. Patients with asthma HP asthma MESHD and COVID-19 were older and were at increased risk due to comorbidity-related factors. ICS and biologics are generally safe and may be associated with a protective effect against severe COVID-19 infection MESHD.

    Confirmed central olfactory system lesions on brain MRI in COVID-19 patients with anosmia HP anosmia MESHD: a case-series

    Authors: Yannick Girardeau; Yoan GALLOIS; Guillaume DE BONNECAZE; Bernard ESCUDE; Clarisse LAFONT; Gilles CHATELLIER; Mathieu MARX

    doi:10.1101/2020.07.08.20148692 Date: 2020-07-17 Source: medRxiv

    Objective: Anosmia HP has been listed as a key-symptom associated with the COVID-19 infection MESHD. Because it often occurs without any sign of rhinitis HP rhinitis MESHD, lesions of the central olfactory system have been suspected. To date, however, there is no evidence that anosmia HP anosmia MESHD caused by SARS-CoV2 could be the result of brain damage. Methods: We conducted a case-series on 10 consecutive COVID-19 patients who reported anosmia HP anosmia MESHD. Each patient prospectively underwent a validated olfactory test (Sniffin Sticks test) and a brain MRI. Results: Hypersignal intensity lesions of the central olfactory system were found in 3 subjects on 3D T2 FLAIR and 2D T2 High Resolution images with a lesion involving the olfactory bulbs and/or the orbitofrontal cortex. These 3 subjects showed a severe and persistent loss of smell on the olfactory test. Mucosal hyperplasia MESHD of the upper nasal cavities was found in two other subjects with significant smell disorders MESHD. There was no MRI anomaly MESHD in two subjects with good smell restoration. Conclusions: Anomalies of the central olfactory system could be responsible for anosmia HP anosmia MESHD in patients with COVID-19 infection MESHD. Further studies are needed to assess the impact on long-term functional prognosis of these lesions.

    Clinical severity and epidemiological spectrum of coronavirus disease MESHD 2019 in children TRANS – comparison with influenza

    Authors: Maria Pokorska-Śpiewak; Ewa Talarek; Jolanta Popielska; Karolina Nowicka; Agnieszka Ołdakowska; Konrad Zawadka; Barbara Kowalik-Mikołajewska; Anna Tomasik; Anna Dobrzeniecka; Marta Lipińska; Beata Krynicka-Czech; Urszula Coupland; Aleksandra Stańska-Perka; Małgorzata Ludek; Magdalena Marczyńska

    doi:10.21203/rs.3.rs-32960/v1 Date: 2020-06-01 Source: ResearchSquare

    Data on the novel coronavirus disease MESHD 2019 (COVID-19) in children TRANS are limited, and studies from Europe are scarce. We analyzed the clinical severity and epidemiologic aspects of COVID-19 in consecutive children TRANS aged TRANS 0 – 18 years, referred with a suspicion of COVID-19 between February 1, and April 15, 2020. RT-PCR on a nasopharyngeal swab was used to confirm COVID-19. 319 children TRANS met the criteria of a suspected case. COVID-19 was diagnosed in 15/319 (4.7%) patients (8 male TRANS; mean age TRANS 10.5 years). All of them had household contact TRANS with an infected relative. Five (33.3%) patients were asymptomatic TRANS. In 9/15 (60.0%) children TRANS, the course of the disease was mild, and in 1/15 (6.7%), it was moderate, with the following symptoms: fever HP fever MESHD (46.7%), cough HP (40%), diarrhea HP diarrhea MESHD (20%), vomiting HP vomiting MESHD (13.3%), rhinitis HP rhinitis MESHD (6.7%), and shortness of breath MESHD (6.7%). In the COVID-19-negative patients, other infections were confirmed TRANS infections were confirmed MESHD, including influenza in 32/319 (10%). The clinical course of COVID-19 and influenza differed significantly based on the clinical presentation. In conclusion, the clinical course of COVID-19 in children TRANS is usually mild or asymptomatic TRANS. In children TRANS suspected of having COVID-19, other infections should not be overlooked. The main risk factor for COVID-19 in children TRANS is household contact TRANS with an infected relative.

    Effect of Dietary Modification for Targeting Histamine Activity in Patients of Allergic Rhinitis HP Allergic Rhinitis MESHD: a Randomised Open Label Study

    Authors: Mohsin Ali Khan; Zaw Ali Khan; Abdul Naeem; Nigar Naqvi; Shikha Srivastava; Anuja Bhargava; Rajeev Krishna Gupta

    doi:10.21203/rs.3.rs-25717/v1 Date: 2020-04-27 Source: ResearchSquare

    Allergic Rhinitis HP Allergic Rhinitis MESHD refers to immunoglobulin E mediated inflammation MESHD of the nasal cavity. Mast cell activation releases histamine, the inflammatory mediator that plays a central role in the biochemical mechanism of this disease. It is metabolised by Diamine Oxidase (DAO) and Histamine N-methyltransferase (HNMT). In this randomised open label study, we recruited 60 patients out of which 30 patients were provided standard treatment and 30 were provided standard treatment along with instructions for dietary modification. The dietary modification consisted of excluding commonly consumed histamine-rich foods and foods containing pro-histamine or anti-DAO active constituents. Each patient was followed up 3 times over the course of 15 days. The patients in the dietary modification group showed significant improvement in rhinitis HP rhinitis MESHD symptoms within 7 days, while the control group’s improvement was not significant in the same amount of time. The overall improvement between the first and last visits was more significant in the dietary modification group as compared to the control group. Thus, the exclusion of histamine-rich foods and foods containing pro-histamine or anti-DAO compounds may be recommended to patients of allergic rhinitis HP allergic rhinitis MESHD for quicker and better recovery. This approach may also be explored in other conditions where histamine is implicated such as asthma HP asthma MESHD and infections caused by coronaviruses.

    Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs

    Authors: Ujjwal Neogi; Kyle J. Hill; Anoop T. Ambikan; Xiao Heng; Thomas P. Quinn; Siddappa N. Byrareddy; Anders Sönnerborg; Stefan G. Sarafianos; Kamal Singh

    id:10.20944/preprints202004.0184.v1 Date: 2020-04-12 Source: Preprints.org

    Coronaviruses (CoVs) are positive-stranded RNA viruses that infect MESHD humans and animals. Infection by CoVs such as HCoV-229E, -NL63, -OC43 and -HKUI1 leads to the common cold, short lasting rhinitis HP rhinitis MESHD, cough HP, sore throat and fever HP fever MESHD. However, CoVs such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV) MESHD, and the newest SARS-CoV-2 (the causative agent of COVID-19) lead to severe and deadly diseases MESHD with mortality rates ranging between ~1 to 35% depending on factors such as age TRANS and pre-existing conditions. Despite continuous global health threats to human, there are no approved vaccines or drugs targeting human CoVs, and the recent outbreak of COVID-19 emphasizes an urgent need for therapeutic interventions. Using computational and bioinformatics tools, here we present the feasibility of reported broad-spectrum RNA polymerase inhibitors as anti- SARS-CoV-2 drugs targeting its main RNA polymerase, suggesting that investigational and approved nucleoside RNA polymerase inhibitors have potential as anti-SARS-CoV-2 drugs. However, we note that it is also possible for SARS-CoV-2 to evolve and acquire drug resistance mutations against these nucleoside inhibitors.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.